{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T16:11:15Z","timestamp":1765728675751},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T00:00:00Z","timestamp":1525219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s12471-018-1118-0","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T08:22:26Z","timestamp":1525249346000},"page":"311-320","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Optimal long-term antithrombotic management of atrial fibrillation: life cycle management"],"prefix":"10.1007","volume":"26","author":[{"given":"R.","family":"Pisters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Elvan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. J. G. M.","family":"Crijns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. E. W.","family":"Hemels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,2]]},"reference":[{"key":"1118_CR1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983\u20138.","journal-title":"Stroke"},{"key":"1118_CR2","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, et\u00a0al. ESC AF 2016. Eur Heart\u00a0J. 2016;37:2893\u2013962.","journal-title":"Eur Heart J"},{"key":"1118_CR3","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/europace\/euq080","volume":"12","author":"R Pisters","year":"2010","unstructured":"Pisters R, van Oostenbrugge RJ, Knottnerus ILH, et\u00a0al. The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines. Europace. 2010;12:779\u201384.","journal-title":"Europace"},{"key":"1118_CR4","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.ejcts.2009.12.033","volume":"37","author":"A Ahlsson","year":"2010","unstructured":"Ahlsson A, Fengsrud E, Bodin L, Englund A. Postoperative atrial fibrillation in patients undergoing aortocoronary bypass surgery carries an eightfold risk of future atrial fibrillation and a\u00a0doubled cardiovascular mortality. Eur J Cardiothorac Surg. 2010;37:1353\u20139.","journal-title":"Eur J Cardiothorac Surg"},{"key":"1118_CR5","first-page":"1323","volume":"17","author":"\u00d6 Erk\u00fcner","year":"2017","unstructured":"Erk\u00fcner \u00d6, Rienstra M, Van Gelder IC, et al. Stroke risk in patients with device-detected atrial high-rate episodes. Neth Heart\u00a0J. 2017;17:1323\u20135.","journal-title":"Neth Heart J"},{"key":"1118_CR6","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1093\/eurheartj\/ehx042","volume":"38","author":"IC Gelder Van","year":"2017","unstructured":"Van Gelder IC, Healey JS, Crijns HJGM, et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart\u00a0J. 2017;38:1339\u201344.","journal-title":"Eur Heart J"},{"key":"1118_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/europace\/euw279","volume":"19","author":"AJ Camm","year":"2017","unstructured":"Camm AJ, Simantirakis E, Goette A, et al. Atrial high-rate episodes and stroke prevention. Europace. 2017;19:169\u201379.","journal-title":"Europace"},{"key":"1118_CR8","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/S0002-8703(03)00086-3","volume":"145","author":"IA Khan","year":"2003","unstructured":"Khan IA. Atrial stunning: determinants and cellular mechanisms. Am Heart\u00a0J. 2003;145:787\u201394.","journal-title":"Am Heart J"},{"key":"1118_CR9","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0002-9149(98)00704-8","volume":"82","author":"M Berger","year":"1998","unstructured":"Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a\u00a0retrospective analysis. Am J Cardiol. 1998;82:1545\u20137\u2013A8.","journal-title":"Am. J. Cardiol."},{"key":"1118_CR10","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/0735-1097(94)90652-1","volume":"23","author":"WJ Manning","year":"1994","unstructured":"Manning WJ, Silverman DI, Katz SE, et\u00a0al. Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J\u00a0Am Coll Cardiol. 1994;23:1535\u201340.","journal-title":"J. Am. Coll. Cardiol."},{"key":"1118_CR11","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jacc.2010.05.028","volume":"56","author":"R Marinigh","year":"2010","unstructured":"Marinigh R, Lip GYH, Fiotti N, et\u00a0al. Age as a\u00a0risk factor for stroke in atrial fibrillation patients. J\u00a0Am Coll Cardiol. 2010;56:827\u201337.","journal-title":"J. Am. Coll. Cardiol."},{"key":"1118_CR12","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/j.hrthm.2012.08.013","volume":"9","author":"B Weijs","year":"2012","unstructured":"Weijs B, Pisters R, Haest RJ, et\u00a0al. Patients originally diagnosed with idiopathic atrial fibrillation more often suffer from insidious coronary artery disease compared to healthy sinus rhythm controls. Heart Rhythm. 2012;9:1923\u20139.","journal-title":"Heart Rhythm"},{"key":"1118_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/heartjnl-2012-302843","volume":"99","author":"ACE Scowcroft","year":"2013","unstructured":"Scowcroft ACE, Lee S, Mant J. Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the General Practice Research Database (GPRD) 2000\u20132009. Heart. 2013;99:127\u201332.","journal-title":"Heart"},{"key":"1118_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cjca.2015.05.012","volume":"32","author":"Lefebvre M\u2011CD","year":"2016","unstructured":"Lefebvre M\u2011CD, St-Onge M, Glazer-Cavanagh M, et al. The effect of bleeding risk and frailty status on anticoagulation patterns in octogenarians with atrial fibrillation: the FRAIL-AF study. Can J Cardiol. 2016;32:169\u201376.","journal-title":"Can. J. Cardiol."},{"key":"1118_CR15","first-page":"1765","volume":"27","author":"I Induruwa","year":"2017","unstructured":"Induruwa I, Evans NR, Aziz A, et al. Clinical frailty is independently associated with non-prescription of anticoagulants in older patients with atrial fibrillation. Geriatr Gerontol Int. 2017;27:1765.","journal-title":"Geriatr Gerontol Int"},{"key":"1118_CR16","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R. A novel user-friendly score (HAS-BLED) to assess 1\u2011year risk of major bleeding in patients with atrial fibrillation. Chest. 2010;138:1093\u2013100.","journal-title":"Chest"},{"key":"1118_CR17","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1111\/jth.13361","volume":"14","author":"J Jaspers Focks","year":"2016","unstructured":"Jaspers Focks J, van Vugt SPG, Albers-Akkers MTH, et al. Low performance of bleeding risk models in the very elderly with atrial fibrillation using vitamin K antagonists. J\u00a0Thromb Haemost. 2016;14:1715\u201324.","journal-title":"J Thromb Haemost"},{"key":"1118_CR18","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1161\/CIRCULATIONAHA.110.007864","volume":"124","author":"D Poli","year":"2011","unstructured":"Poli D, Antonucci E, Testa S, et\u00a0al. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a\u00a0prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation. 2011;124:824\u20139.","journal-title":"Circulation"},{"key":"1118_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/ageing\/afv156","volume":"45","author":"KH Ng","year":"2016","unstructured":"Ng KH, Shestakovska O, Connolly SJ, et\u00a0al. Efficacy and safety of apixaban compared with aspirin in the elderly: a\u00a0subgroup analysis from the AVERROES trial. Age Ageing. 2016;45:77\u201383.","journal-title":"Age Ageing"},{"key":"1118_CR20","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jacc.2009.05.046","volume":"54","author":"D Poli","year":"2009","unstructured":"Poli D, Antonucci E, Grifoni E, et\u00a0al. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J\u00a0Am Coll Cardiol. 2009;54:999\u20131002.","journal-title":"J. Am. Coll. Cardiol."},{"key":"1118_CR21","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1136\/bmj.320.7246.1380","volume":"320","author":"J Protheroe","year":"2000","unstructured":"Protheroe J, Fahey T, Montgomery AA, Peters TJ. The impact of patients\u2019 preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ. 2000;320:1380\u20134.","journal-title":"BMJ"},{"key":"1118_CR22","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/ageing\/afh202","volume":"33","author":"R Fuller","year":"2004","unstructured":"Fuller R, Dudley N, Blacktop J. Avoidance hierarchies and preferences for anticoagulation \u2013 semi-qualitative analysis of older patients\u2019 views about stroke prevention and the use of warfarin. Age Ageing. 2004;33:608\u201311.","journal-title":"Age Ageing"},{"key":"1118_CR23","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","volume":"370","author":"J Mant","year":"2007","unstructured":"Mant J, Hobbs FR, Fletcher K, et\u00a0al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a\u00a0randomised controlled trial. Lancet. 2007;370:493\u2013503.","journal-title":"Lancet"},{"key":"1118_CR24","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1056\/NEJMoa1007432","volume":"364","author":"SJ Connolly","year":"2011","unstructured":"Connolly SJ, Eikelboom J, Joyner C, et\u00a0al. Apixaban in patients with atrial fibrillation. N\u00a0Engl J Med. 2011;364:806\u201317.","journal-title":"N Engl J Med"},{"key":"1118_CR25","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","volume":"367","author":"S Connolly","year":"2006","unstructured":"ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, et\u00a0al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a\u00a0randomised controlled trial. Lancet. 2006;367:1903\u201312.","journal-title":"Lancet"},{"key":"1118_CR26","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1093\/ageing\/afv071","volume":"44","author":"A Wolff","year":"2015","unstructured":"Wolff A, Shantsila E, Lip GYH, Lane DA. Impact of advanced age on management and prognosis in atrial fibrillation: insights from a\u00a0population-based study in general practice. Age Ageing. 2015;44:874\u20138.","journal-title":"Age Ageing"},{"key":"1118_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/joim.12683","volume":"283","author":"L Staerk","year":"2018","unstructured":"Staerk L, Gerds TA, Lip GYH, et\u00a0al. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a\u00a0nationwide cohort study. J\u00a0Intern Med. 2018;283:45\u201355.","journal-title":"J Intern Med"},{"key":"1118_CR28","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","volume":"68","author":"BA Steinberg","year":"2016","unstructured":"Steinberg BA, Shrader P, Thomas L, et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II Registry. J\u00a0Am Coll Cardiol. 2016;68:2597\u2013604.","journal-title":"J Am Coll Cardiol"},{"key":"1118_CR29","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s40266-017-0466-6","volume":"34","author":"M Wehling","year":"2017","unstructured":"Wehling M, Collins R, Gil VM, et al. Appropriateness of Oral Anticoagulants for the Long-Term Treatment of Atrial Fibrillation in Older People: results of an evidence-based review and international consensus validation process (OAC-FORTA 2016). Drugs Aging. 2017;34:499\u2013507.","journal-title":"Drugs Aging"},{"issue":"8","key":"1118_CR30","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1177\/1076029615581365","volume":"22","author":"B Kilickiran Avci","year":"2015","unstructured":"Kilickiran Avci B, Vatan B, Tok OO, et al. The trends in utilizing nonvitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation: a real-life experience. Clin Appl Thromb Hemost. 2015;22(8):785\u201391.","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"1118_CR31","doi-asserted-by":"publisher","first-page":"e003074","DOI":"10.1161\/JAHA.115.003074","volume":"5","author":"X Yao","year":"2016","unstructured":"Yao X, Abraham NS, Alexander GC, et\u00a0al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J\u00a0Am Heart Assoc. 2016;5:e3074\u201312.","journal-title":"J Am Heart Assoc"},{"key":"1118_CR32","first-page":"806","volume":"364","author":"R Pisters","year":"2017","unstructured":"Pisters R, van Vugt SPG, Brouwer MA, et al. Real-life use of Rivaroxaban in the Netherlands: data from the\u00a0Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation\u00a0(XANTUS) registry. Neth Heart\u00a0J. 2017;364:806\u20138.","journal-title":"Neth Heart J"},{"key":"1118_CR33","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et\u00a0al. Edoxaban versus warfarin in patients with atrial fibrillation. N\u00a0Engl J Med. 2013;369:2093\u2013104.","journal-title":"N Engl J Med"},{"issue":"6","key":"1118_CR34","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1001\/jamacardio.2016.1829","volume":"1","author":"JH Alexander","year":"2016","unstructured":"Alexander JH, Andersson U, Lopes RD, et\u00a0al. Apixaban 5\u202fmg twice daily and clinical outcomes in patients with atrial fibrillation and advanced age, low body weight, or high creatinine. JAMA Cardiol. 2016;1(6):673\u201381. \n                    https:\/\/doi.org\/10.1001\/jamacardio.2016.1829\n                    \n                  .","journal-title":"JAMA Cardiol."},{"key":"1118_CR35","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1056\/NEJMp1103050","volume":"364","author":"BN Beasley","year":"2011","unstructured":"Beasley BN, Unger EF, Temple R. Anticoagulant options \u2013 why the FDA approved a\u00a0higher but not a\u00a0lower dose of dabigatran. N\u00a0Engl J Med. 2011;364:1788\u201390.","journal-title":"N Engl J Med"},{"key":"1118_CR36","volume-title":"Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation","author":"DE Clarkesmith","year":"1996","unstructured":"Clarkesmith DE, Pattison HM, Khaing PH, Lane DA. Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. Chichester: John Wiley & Sons, Ltd; 1996. Lane DA, ed."},{"key":"1118_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12875-017-0588-2","volume":"18","author":"V Maikranz","year":"2017","unstructured":"Maikranz V, Siebenhofer A, Ulrich L\u2011R, et al. Does a\u00a0complex intervention increase patient knowledge about oral anticoagulation? \u2013 a\u00a0cluster-randomised controlled trial. BMC Fam Pract. 2017;18:15.","journal-title":"BMC Fam. Pract."},{"key":"1118_CR38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.amjcard.2014.10.006","volume":"115","author":"JM Ashburner","year":"2015","unstructured":"Ashburner JM, Go AS, Reynolds K, et al. Comparison of frequency and outcome of major gastrointestinal hemorrhage in patients with atrial fibrillation on versus not receiving warfarin therapy (from the ATRIA and ATRIA-CVRN cohorts). Am J Cardiol. 2015;115:40\u20136.","journal-title":"Am. J. Cardiol."},{"key":"1118_CR39","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.amjcard.2013.10.044","volume":"113","author":"W Qureshi","year":"2014","unstructured":"Qureshi W, Mittal C, Patsias I, et\u00a0al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol. 2014;113:662\u20138.","journal-title":"Am. J. Cardiol."},{"key":"1118_CR40","doi-asserted-by":"publisher","first-page":"h5876","DOI":"10.1136\/bmj.h5876","volume":"351","author":"L Staerk","year":"2015","unstructured":"Staerk L, Lip GYH, Olesen JB, et\u00a0al. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ. 2015;351:h5876.","journal-title":"BMJ"},{"key":"1118_CR41","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/ajg.2014.398","volume":"110","author":"N Sengupta","year":"2015","unstructured":"Sengupta N, Feuerstein JD, Patwardhan VR, et\u00a0al. The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a\u00a0prospective study. Am J Gastroenterol. 2015;110:328\u201335.","journal-title":"Am J Gastroenterol"},{"key":"1118_CR42","doi-asserted-by":"publisher","first-page":"e5467","DOI":"10.1097\/MD.0000000000005467","volume":"95","author":"S-J Lee","year":"2016","unstructured":"Lee S\u2011J, Sung J\u2011H, Kim J\u2011B, et al. The safety and efficacy of vitamin K antagonist in atrial fibrillation patients with previous ulcer bleeding: long-term results from a\u00a0multicenter study. Medicine (Baltimore). 2016;95:e5467.","journal-title":"Medicine (Baltimore)"},{"key":"1118_CR43","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.3109\/0886022X.2013.819766","volume":"35","author":"F Khalid","year":"2013","unstructured":"Khalid F, Qureshi W, Qureshi S, et\u00a0al. Impact of restarting warfarin therapy in renal disease anticoagulated patients with gastrointestinal hemorrhage. Ren Fail. 2013;35:1228\u201335.","journal-title":"Ren Fail"},{"key":"1118_CR44","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.amjcard.2012.03.036","volume":"110","author":"S-J Lee","year":"2012","unstructured":"Lee S\u2011J, Shin D\u2011H, Hwang H\u2011J, et al. Bleeding risk and major adverse events in patients with previous ulcer on oral anticoagulation therapy. Am J Cardiol. 2012;110:373\u20137.","journal-title":"Am. J. Cardiol."},{"issue":"6","key":"1118_CR45","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1161\/CIRCULATIONAHA.115.015735","volume":"132","author":"P Bronnum Nielsen","year":"2015","unstructured":"Bronnum Nielsen P. Restarting anticoagulant treatment after Intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding. Circulation. 2015;132(6):517\u201325. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.015735\n                    \n                  .","journal-title":"Circulation"},{"key":"1118_CR46","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1161\/STROKEAHA.115.009087","volume":"46","author":"J Pennlert","year":"2015","unstructured":"Pennlert J, Asplund K, Carlberg B, et\u00a0al. Antithrombotic treatment following intracerebral hemorrhage in patients with and without atrial fibrillation. Stroke. 2015;46:2094\u20139.","journal-title":"Stroke"},{"key":"1118_CR47","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1136\/jnnp-2013-306476","volume":"85","author":"MTC Poon","year":"2014","unstructured":"Poon MTC, Fonville AF, Al-Shahi Salman R. Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis. J\u00a0Neurol Neurosurg Psychiatr. 2014;85:660\u20137.","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"1118_CR48","first-page":"A8507","volume":"159","author":"LJJ Kappelle","year":"2015","unstructured":"Kappelle LJJ, Hofmeijer J, Chamuleau SA, et\u00a0al. Resumption of antithrombotic treatment after an intracerebral haemorrhage. Ned Tijdschr Geneeskd. 2015;159:A8507.","journal-title":"Ned Tijdschr Geneeskd"},{"key":"1118_CR49","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1161\/STROKEAHA.117.016902","volume":"48","author":"P Appelros","year":"2017","unstructured":"Appelros P, Farahmand B, Ter\u00e9nt A, \u00c5sberg S. To treat or not to treat. Stroke. 2017;48:1617\u201323.","journal-title":"Stroke"},{"key":"1118_CR50","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1161\/STROKEAHA.115.008891","volume":"46","author":"M Paciaroni","year":"2015","unstructured":"Paciaroni M, Agnelli G, Falocci N, et\u00a0al. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF study. Stroke. 2015;46:2175\u201382.","journal-title":"Stroke"},{"key":"1118_CR51","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1161\/STROKEAHA.116.015770","volume":"48","author":"M Paciaroni","year":"2017","unstructured":"Paciaroni M, Agnelli G, Caso V, et\u00a0al. Prediction of early recurrent thromboembolic event and major bleeding in patients with acute stroke and atrial fibrillation by a\u00a0risk stratification schema: the ALESSA Score Study. Stroke. 2017;48:726\u201332.","journal-title":"Stroke"},{"key":"1118_CR52","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1161\/STROKEAHA.113.675140","volume":"44","author":"JM Leyden","year":"2013","unstructured":"Leyden JM, Kleinig TJ, Newbury J, et\u00a0al. Adelaide stroke incidence study: declining stroke rates but many preventable cardioembolic strokes. Stroke. 2013;44:1226\u201331.","journal-title":"Stroke"},{"key":"1118_CR53","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et\u00a0al. Dabigatran versus warfarin in patients with atrial fibrillation. N\u00a0Engl J Med. 2009;361:1139\u201351.","journal-title":"N Engl J Med"},{"key":"1118_CR54","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, et\u00a0al. Apixaban versus warfarin in patients with atrial fibrillation. N\u00a0Engl J Med. 2011;365:981\u201392.","journal-title":"N Engl J Med"},{"key":"1118_CR55","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1111\/jth.13427","volume":"14","author":"G Bertozzo","year":"2016","unstructured":"Bertozzo G, Zoppellaro G, Granziera S, et al. Reasons for and consequences of vitamin K antagonist discontinuation in very elderly patients with non-valvular atrial fibrillation. J\u00a0Thromb Haemost. 2016;14:2124\u201331.","journal-title":"J Thromb Haemost"},{"key":"1118_CR56","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy136","author":"J Steffel","year":"2018","unstructured":"Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulation in patients with atrial fibrillation. Eur Heart\u00a0J. 2018; \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehy136\n                    \n                  .","journal-title":"Eur Heart J"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12471-018-1118-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-018-1118-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-018-1118-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T00:09:42Z","timestamp":1556755782000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12471-018-1118-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,2]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["1118"],"URL":"https:\/\/doi.org\/10.1007\/s12471-018-1118-0","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,2]]},"assertion":[{"value":"2 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.\u00a0Pisters, A.\u00a0Elvan, H.J.G.M.\u00a0Crijns and M.E.W.\u00a0Hemels declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}